10-Q: Silo Pharma Reports Q2 2026 Results, Focus on R&D

Silo Pharma, Inc. filed its Q2 2026 Form 10-Q, detailing ongoing research and development efforts in biopharmaceuticals and a cryptocurrency treasury strategy, alongside financial results showing continued net losses.

Summary

• Silo Pharma, Inc. (Silo) filed its Form 10-Q for the quarterly period ended June 30, 2026.
• The company reported a net loss of $832,829 for the three months ended June 30, 2026, and $2,479,946 for the six months ended June 30, 2026.
• Total operating expenses for the three months ended June 30, 2026, were $928,949, a decrease from $1,265,117 in the same period of 2025.
• Research and development expenses for the three months ended June 30, 2026, were $298,418, a decrease from $717,247 in the prior year period.
• The company's cryptocurrency treasury strategy includes assets like Bitcoin, Ethereum, and Solana.
• Silo completed a 1-for-15 reverse stock split effective June 2, 2026.
• Subsequent to the quarter, on July 9, 2026, the company closed a private placement raising approximately $4 million in gross proceeds.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant net losses, a decrease in working capital, and the ongoing need for financing, despite progress in R&D and recent capital raises.

Positives

• The company has a diversified pipeline with four product candidates: SPC-15 (PTSD/anxiety), SP-26 (fibromyalgia/pain), SPC-14 (Alzheimer's), and SPU-16 (CNS disorders).
• Progress is being made on SPC-15, with GLP-compliant pharmacokinetic and pharmacodynamic studies underway and an aim for an IND submission in 2026.
• The company secured approximately $4 million in gross proceeds from a July 2026 private placement to fund working capital and general corporate purposes.
• Working capital was $4,647,793 as of June 30, 2026, and the company believes it has sufficient cash to meet obligations for at least twelve months.
• The company is exploring the potential of psychedelic drugs like psilocybin and ketamine for various medical conditions.

Negatives

• The company reported a net loss of $832,829 for the three months ended June 30, 2026, and $2,479,946 for the six months ended June 30, 2026.
• There was a significant decrease in revenues, with $0 reported for the three months ended June 30, 2026, compared to $18,025 in the prior year period, due to the expiration of a license agreement.
• Working capital decreased by 31.0% to $4,647,793 as of June 30, 2026, from $6,737,542 as of December 31, 2025.
• Net cash used in operating activities was $1,604,484 for the six months ended June 30, 2026.
• The company has an accumulated deficit of $21,972,335 as of June 30, 2026.
• The company recorded an impairment loss of $29,911 related to its holdings of LsETH and mSOL crypto assets.

Risks

• The company's ability to obtain additional funds for its operations is a significant risk.
• Risks related to the timing and costs of clinical trials and other expenses.
• Market acceptance of products and intellectual property risks are potential challenges.
• The impact of government regulation and developments relating to competitors or the industry.
• The company's competitive position and industry environment are subject to uncertainty.
• Future financial and operating results, including anticipated sources of revenues, are subject to risks.
• The company's ability to attract and retain qualified key management and technical personnel.

Future Outlook

The company expects its research and development activities to increase as it develops existing product candidates and potentially acquires new ones, reflecting increasing costs associated with in-licensed products, CRO agreements, clinical trial materials, regulatory approvals, and development of its AI subsidiary, Qwikagentsai.

Management Comments

• The company believes that it has sufficient cash and liquid short-term investments to meet its obligations for a minimum of twelve months from the date of this filing.
• The positive working capital and the July 2026 Private Placement serve to mitigate the conditions that historically raised substantial doubt about the Company's ability to continue as a going concern.

Industry Context

StockSavvy.ai notes that Silo Pharma operates in the highly competitive and capital-intensive biopharmaceutical sector, with a dual focus on traditional therapeutics and the emerging field of psychedelic medicine. The company's strategy to license intellectual property from universities and its exploration of the 505(b)(2) regulatory pathway are common approaches in this industry. The inclusion of a cryptocurrency treasury strategy is a less conventional but increasingly seen diversification tactic.

Comparison to Industry Standards

• Biopharmaceutical companies at the developmental stage typically incur significant R&D expenses, as seen with Silo Pharma's $1.3 million in R&D costs for the first six months of 2026.
• Many developmental-stage biopharma companies rely on frequent capital raises (equity or debt) to fund operations, similar to Silo Pharma's May 2025 and July 2026 offerings.
• The use of the 505(b)(2) regulatory pathway is a standard strategy to potentially expedite drug approval by leveraging existing FDA-approved drug data, a path Silo Pharma is pursuing for SPC-15.
• The company's focus on underserved conditions like PTSD and Alzheimer's aligns with industry trends seeking treatments for significant unmet medical needs.

Legal Proceedings

• The company is not currently aware of any legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on its business, financial condition, or operating results.

Stakeholder Impact

• Shareholders may be impacted by the dilutive effect of recent and future capital raises and the reverse stock split.
• Employees and management are subject to stock-based compensation plans, as detailed in the filing.
• Creditors and suppliers are subject to the company's liquidity and ability to meet its financial obligations.

Next Steps

• Aiming for an IND submission in 2026 for SPC-15.
• Continue GLP-compliant pharmacokinetic and pharmacodynamic studies for SPC-15.
• Develop existing product candidates and potentially acquire new ones.
• Increase research and development activities, including those related to Qwikagentsai.
• Utilize proceeds from the July 2026 Offering for working capital and general corporate purposes.

Key Dates

Recommendation

Silo Pharma is a developmental-stage company with significant net losses and an ongoing need for capital. While progress is being made in R&D and recent capital raises provide some runway, the inherent risks in drug development and the company's financial situation warrant a cautious approach. A 'hold' recommendation reflects the potential for future upside if pipeline candidates advance successfully, balanced against the substantial risks and uncertainties.

Keywords

biopharmaceutical, drug development, cryptocurrency, AI technology, reverse stock split, clinical trials, Nasdaq, SEC filing